Hematopoietic Stem Cell Transplant for Hematological Malignancies: Experience from a Tertiary Care Center in Northern India and Review of Indian Data

• Published in: South Asian journal of cancer 2022-01, Vol.11 (1), p.062-067
• Main Authors: Sharma, Sanjeev Kumar, Choudhary, Dharma, Doval, Divya, Khandelwal, Vipin, Setia, Rasika, Dadu, Tina, Handoo, Anil
• Format: Article
• Language: English
• Subjects: allogeneic; gvhd; haploidentical; infections; leukemia; lymphoma; matched sibling donor; myeloma; Original; Original Article; overall survival; stem cell transplant
• ISSN: 2278-330X; 2278-4306
• DOI: 10.1055/s-0041-1731599

Abstract 10-1055-s-0041-1731599-i20120197-3.jpg Sanjeev Kumar Sharma Hematopoietic stem cell transplantation (HSCT) is the preferred treatment for high-risk and relapsed/refractory hematological malignancies. Moreover, with the improved supportive care and increasing acceptance of haploidentical transplantations as an alternative treatment modality, more patients are opting for HSCT as a definite treatment for hematological malignancies. We report here the real-world data and outcome of HSCT done for hematological malignancies at our transplant center. Five hundred and sixteen patients underwent HSCT from August 2010 to November 2019. The most common indications for allogeneic and autologous HSCT were acute myeloid leukemia and multiple myeloma, respectively. The 5-year overall survival and disease-free survival for all transplants were 65% and 33%, respectively. Though outcome of matched sibling donor allogeneic transplant is better than haploidentical donor (HID) transplant, patients having only HID can still be considered for allogeneic HSCT for high-risk diseases. The most common cause of death was infections followed by relapse of the disease.